Venezuela Interim President Defends Earthquake Response as Death Toll Climbs 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Trump Offers to Help Advance Ukraine Peace Talks in Call With Putin 
Air Force Investigates Officer After Capitol Protest Calling for Trump, Vance Impeachment 
Russia’s Deadly Kyiv Missile and Drone Attack Kills 27 as Zelensky Urges Faster Air Defense Support 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Australian PM Anthony Albanese Apologizes After Kylie Minogue Podcast Remarks Spark Backlash 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
US Appeals Court Limits ICE Detention Without Bond Hearings After 90 Days 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Michigan Senate Race Narrows as Mallory McMorrow Ends Democratic Campaign 
Iran Begins Oil Sale Talks With Japan Under U.S. Sanctions Waiver Amid Shipping Risks 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
